On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.
Nordic Nanovector – Annual and Remuneration Reports Approved Read More »
NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Everest Medicines announced that it has signed an MOU for comprehensive strategic cooperation with Guangdong Academy of Medical Sciences in renal disease research, scientific innovation and translational studies.
The Chemours Company, a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, announces the appointment of Denise Dignam as President, Chemours Titanium Technologies and Chemical Solutions, effective April 1, 2023.
Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement Read More »
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 8:00 a.m. ET.
Karuna Therapeutics to Present at the Stifel 2023 CNS Days Read More »
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.
POXEL SA announced that is has finalized agreements with its lenders to restructure its existing debt obligations and a new equity-linked financing with IRIS with an initial drawdown of EUR 3.5 million.
POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its results for the year ended December 31, 2022 and provided a corporate update.
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update Read More »
PureTech Health plc and Royalty Pharma announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.
